LAV BASTA 48
Alternative Names: LAV-BASTA-48Latest Information Update: 31 Mar 2025
At a glance
- Originator Elusys Therapeutics
- Developer Elusys Therapeutics; Israel Institute for Biological Research
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anthrax